istock-839222794-nicoelnino
NicoElnino / iStockphoto.com
8 May 2018Big Pharma

Japanese Takeda to acquire Shire for $62bn

Japanese pharmaceutical company Takeda has agreed to acquire biotech company Shire for $62 billion.

Takeda announced the news today, May 8.

Takeda is the largest pharmaceutical in Japan. The company’s work centres on oncology, gastroenterology, and central nervous system disease. Takeda’s research and development also includes vaccines.

Shire focuses its research on discovering therapies for rare diseases, although the Irish company is well-known for its attention deficit hyperactivity disorder drug Adderall. Last month, Shire enjoyed victory when a US judge found that a proposed Abbreviated New Drug Application infringes claims of Shire’s Adderrall patents.

Shire had previously rejected four offers from Takeda, and the agreement has been made on the final day that the Japanese company would have been able to put in another bid. According to Reuters, previous offers were rejected due to price concerns and Takeda’s intention to pay for much of the acquisition in stock.

Last month Shire revealed that it had plans to sell its oncology business to France-based pharmaceutical company Servier for $2.4 billion.

For the deal between Takeda and Shire to proceed, 75% of Shire’s voting shareholders must support the transaction.

Since the beginning of 2018, there has been a flood of merger and acquisition activity.

In January, Celgene  said it would acquire Juno Therapeutics for $9 billion, in a bid to discover and develop “transformative medicines for patients with incurable blood cancers”.

This was followed by Sanofi’s  announcement that it would buy biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

Johnson & Johnson recently  stated that it would sell LifeScan, its blood glucose monitoring unit, for $2.1 billion to a private investment firm.

Novartis shared its intention to acquire gene-therapy company AveXis for $8.7 billion last month, just after GSK revealed that it would buy Novartis out of their joint consumer healthcare business.

Last month Sanofi confirmed it was negotiating the sale of its European generics business for €1.9 billion, following which Procter & Gamble announced plans to buy the consumer health business of  Merck KGaA for €3.4 billion.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Americas
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Big Pharma
31 October 2018   Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.
Americas
25 June 2019   US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.

More on this story

Americas
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Big Pharma
31 October 2018   Japan-based Takeda Pharmaceuticals is reportedly planning to sell its European over-the-counter business to lessen its debt from acquiring biotech company Shire.
Americas
25 June 2019   US drug maker AbbVie has agreed to buy Allergan, the Ireland-headquartered maker of Botox, for $63 billion, in the latest blockbuster deal for the pharmaceutical industry.